222 related articles for article (PubMed ID: 21366650)
1. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
[TBL] [Abstract][Full Text] [Related]
2. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients.
Miura M; Inoue K; Kagaya H; Satoh S; Tada H; Sagae Y; Habuchi T; Suzuki T
Biopharm Drug Dispos; 2007 May; 28(4):167-75. PubMed ID: 17377957
[TBL] [Abstract][Full Text] [Related]
3. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
[TBL] [Abstract][Full Text] [Related]
4. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
5. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
6. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
[TBL] [Abstract][Full Text] [Related]
7. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
[TBL] [Abstract][Full Text] [Related]
8. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
Ciftci HS; Karadeniz MS; Tefik T; Caliskan Y; Yazıcı H; Demir E; Turkmen A; Nane I; Oguz FS; Aydin F
Transplant Proc; 2017 Apr; 49(3):490-496. PubMed ID: 28340819
[TBL] [Abstract][Full Text] [Related]
9. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
Hosohata K; Masuda S; Katsura T; Takada Y; Kaido T; Ogura Y; Oike F; Egawa H; Uemoto S; Inui K
Drug Metab Dispos; 2009 Apr; 37(4):821-6. PubMed ID: 19139162
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
[TBL] [Abstract][Full Text] [Related]
11. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
Hosohata K; Masuda S; Yonezawa A; Sugimoto M; Takada Y; Kaido T; Ogura Y; Oike F; Uemoto S; Inui K
Drug Metab Pharmacokinet; 2009; 24(5):458-63. PubMed ID: 19881258
[TBL] [Abstract][Full Text] [Related]
12. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
Hosohata K; Masuda S; Ogura Y; Oike F; Takada Y; Katsura T; Uemoto S; Inui K
Drug Metab Pharmacokinet; 2008; 23(2):134-8. PubMed ID: 18445994
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
15. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
[TBL] [Abstract][Full Text] [Related]
16. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation.
Itagaki F; Homma M; Yuzawa K; Fukao K; Kohda Y
Transplant Proc; 2002 Nov; 34(7):2777-8. PubMed ID: 12431607
[No Abstract] [Full Text] [Related]
17. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
[TBL] [Abstract][Full Text] [Related]
18. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
Miura M; Kagaya H; Tada H; Sagae Y; Satoh S; Habuchi T; Suzuki T
Xenobiotica; 2005 May; 35(5):479-86. PubMed ID: 16012079
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
